FDA Adds Black Box Warning to Elevidys After Fatal Liver Failures

FDA adds black box warning to Sarepta's (SRPT) Elevidys, limiting use to walking DMD patients after two deaths from liver failure. Stock rose 9% as investors relieved FDA maintained approval for walking patients rather than pulling drug completely.